The faculty for this program have put together the following resources to help with your treatment of difficult asthma cases.

Several biologic agents are approved or are in phase III trials for use in moderate-to-severe asthma. These medications are monoclonal antibodies that target molecules or receptors involved in asthmatic inflammation.  You can click on the chart do view a PDF copy.

Asthma Action Plan


If you know what to watch for and what steps to take, you will be able to make timely and appropriate decisions about managing your condition help prevent your asthma from getting worse.

EPR-3 Guidelines


The EPR 3 Guidelines on Asthma was developed by an expert panel commissioned by the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee, coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.

Changing Paradigms in the Treatment of Severe Asthma Journal Supplement

Cytokine antagonists are monoclonal antibodies that offer new treatment options for refractory asthma but will also increase complexity because they are effective only for patients with certain asthma subtypes that remain to be more clearly defined.

GINA Guidelines


The 2017 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee.

Asthma Yardstick


Current asthma guidelines recommend a control-based approach to management that involves assessment of impairment and risk followed by implementation of treatment strategies individualized according to the patient’s needs and preferences.

The Asthma Control Test


The Asthma Control Test has been conceived by medical asthma experts and scientifically tested on hundreds of asthmatic sufferers. It provides asthma sufferers and their doctors and nurses with a useful score which will help them determine the level of treatment required.

National Jewish Health
1400 Jackson Street
Denver, CO 80206
© 2017 National Jewish Health

Grant Statement
This educational activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, and Sanofi Genzyme and Regeneron Pharmaceuticals.